antibody

Anti-Dopamine Transporter, C-Terminus

MBS502025

0.1 mL

345 USD

polyclonal

rabbit

nonconjugated

human, mouse

western blot, immunohistochemistry

Antibody

Anti-Dopamine Transporter, C-Terminus

Dopamine Transporter, C-Terminus, Human

sodium-dependent dopamine transporter; Sodium-dependent dopamine transporter; sodium-dependent dopamine transporter; DA transporter; dopamine transporter 1; solute carrier family 6 member 3; solute carrier family 6 (neurotransmitter transporter, dopamine), member 3; solute carrier family 6 (neurotransmitter transporter), member 3; Solute carrier family 6 member 3

SLC6A3

SLC6A3; SLC6A3; DAT; DAT1; PKDYS; DAT1; DA transporter; DAT

SC6A3_HUMAN

Polyclonal

Rabbit

Human, NHP, mouse

620

Specific for the ~88k DAT protein in Western blots.

Affinity Purified (Prepared from rabbit serum by affinity purification using a SulfoLink column matrix to which the peptide immunogen was coupled.)

100 ul in 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 ug per ml BSA and 50% glycerol. Adequate amount of material to conduct 10-mini Western Blots.

For long term storage -20 degree C is recommended. Stable at -20 degree C for at least 1 year.

Western Blot (WB), Immunohistochemistry (IHC)

Quality Control: Western blots performed on each lot. WB: 1:1000. IHC: (frozen sections, formaldehyde fixed tissue; unpublished observations): 1:1000

Antigen: Peptide from the intracellular C-terminus region of human dopamine transporter (DAT), conjugated to keyhole limpet hemocyanin (KLH). Immunogen Information: Synthetic peptide corresponding to amino acid residues from the intracellular C-terminal region conjugated to KLH. Immunogen Species: Human

Species Reactivity Note: The antibody has been tested in Western blots of SDS-solubilized human and mouse striatal samples and in IHC applications with monkey (Macaque) brain sections. Biological Significance: The dopamine transporter (DAT) is responsible for the reaccumulation of dopamine after it has been released. DAT antibodies and antibodies for other markers of catecholamine biosynthesis are widely used as markers for dopaminergic and noradrenergic neurons in a variety of applications including depression, schizophrenia, Parkinson's disease and drug abuse (Kish et al., 2001; Zhu et al., 2000; Zhu et al., 1999). Levels of DAT protein expression are altered by chronic drug administration (Wilson et al., 1996).

Affinity purified rabbit polyclonal antibody

Kish SJ, Kalasinsky KS, Derkach P, Schmunk GA, Guttman M, Ang L, Adams V, Furukawa Y, Haycock JW (2001) Striatal dopaminergic and serotonergic markers in human heroin users. Neuropsychopharmacology 24:561-567. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699-703. Zhu MY, Klimek V, Haycock JW, Ordway GA (2000) Quantitation of tyrosine hydroxylase protein in the locus coeruleus from postmortem human brain. J Neurosci Meth 99:37-44. Zhu MY, Klimek V, Dilley GE, Haycock JW, Stockmeier C, Overholser JC, Meltzer HY, Ordway GA (1999) Elevated levels of tyrosine hydroxylase in the locus coeruleus in major depression. Biol Psychiatry 46:1275-1286.

4507041

NP_001035.1

NM_001044.4

Q01959

68,495 Da

Alcoholism Pathway (585563); Alcoholism Pathway (587116); Alpha-synuclein Signaling Pathway (137913); Amphetamine Addiction Pathway (547607); Amphetamine Addiction Pathway (550546); Cocaine Addiction Pathway (546258); Cocaine Addiction Pathway (546273); Dopamine Clearance From The Synaptic Cleft Pathway (106527); Dopaminergic Synapse Pathway (469199); Dopaminergic Synapse Pathway (469185)

This gene encodes a dopamine transporter which is a member of the sodium- and chloride-dependent neurotransmitter transporter family. The 3' UTR of this gene contains a 40 bp tandem repeat, referred to as a variable number tandem repeat or VNTR, which can be present in 3 to 11 copies. Variation in the number of repeats is associated with idiopathic epilepsy, attention-deficit hyperactivity disorder, dependence on alcohol and cocaine, susceptibility to Parkinson disease and protection against nicotine dependence.[provided by RefSeq, Nov 2009]

Function: Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals. Subunit structure: Homooligomer; disulfide-linked. Interacts with PRKCABP and TGFB1I1. Interacts (via N-terminus) with SYNGR3 (via N-terminus) . By similarity. Interacts with SLC18A2 . By similarity. Ref.13 Ref.14 Ref.15. Subcellular location: Membrane; Multi-pass membrane protein. Involvement in disease: Parkinsonism-dystonia infantile (PKDYS) [MIM:613135]: A neurodegenerative disorder characterized by infantile onset of parkinsonism and dystonia. Other neurologic features include global developmental delay, bradykinesia and pyramidal tract signs.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.19. Miscellaneous: This protein is the target of psychomotor stimulants such as amphetamines or cocaine. Sequence similarities: Belongs to the sodium:neurotransmitter symporter (SNF) (TC 2.A.22) family. SLC6A3 subfamily. [View classification]

0.1 mL

345 USD